Victor W. Nitti, MD, has been appointed by the AUA Board of Directors as the new Chair of the AUA Office of Education.
Victor W. Nitti, MD, has been appointed by the AUA Board of Directors as the new chair of the AUA Office of Education.
Dr. Nitti, professor and vice-chairman of urology at the New York University (NYU) Langone Medical Center in New York, will assume his new role on June 1, 2015, the AUA said in a news release.
Dr. Nitti is also director of Female Pelvic Medicine and Reconstructive Surgery at NYU School of Medicine, where he serves as director of the Female Pelvic Medicine and Reconstructive Surgery fellowship program.
The AUA said Dr. Nitti brings vast experience to his new position, including previous work with the AUA Office of Education, for which he served as both course director and faculty on the AUA annual review course, annual meeting plenary sessions, and numerous female urology courses. Most recently, Dr. Nitti served as a member of the AUA Update Series advisory board, where he was responsible for lessons on urodynamics, female urology, and incontinence.
“We are looking forward to working with Dr. Nitti in his new role as chair of our Office of Education as he continues the AUA’s commitment to providing quality, evidence-based urologic education to our members,” said AUA Secretary-Elect Manoj Monga, MD, who led the search committee for the position. “He brings a sound understanding of global education and new technologies and we are excited about our next steps.”
Next: Dr. Badani joins Mount Sinai
Report questions doc shortage; AUA concerned
IOM report, AUA at odds over GME funding solutions
AUA IC/BPS guideline update highlights new data
In other recent personnel announcements:
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.